SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (204)9/25/2001 3:35:29 AM
From: nigel bates   of 625
 
MELBOURN, England, Sept. 25 /PRNewswire/ -- Cambridge Antibody Technology (Nasdaq: CATG; LSE: CAT) today announced that it has received a CTX (Clinical Trial Exemption) from the UK Medicines Control Agency allowing it to commence phase I/IIa clinical trials in patients with CAT-213, a human anti-eotaxin1 monoclonal antibody.
CAT-213 is in development for the treatment of severe allergic disorders and may also be useful in the management of patients with hypereosinophilia. A phase I study in 25 healthy volunteers was recently completed with no safety concerns after single intravenous doses of up to 10mg/kg.
The new phase I/IIa double-blind clinical trial will take place in two UK investigational sites and will study the effects of CAT-213 or placebo upon patients with allergic rhinitis who are challenged with nasal allergen. It is expected that patient enrollment will commence in October 2001 and be completed before the 2002 UK hay fever season.
Commenting on the news, Dr David Glover, CAT's Medical Director, said, ``We are very pleased to have received approval to start patient trials with CAT-213. The new clinical trial will represent the first human proof of principle study that CAT-213 can modulate the effects of eosinophils in an allergic setting.''
CAT-213 is the fifth human monoclonal antibody from CAT to enter clinical trials and is the third human monoclonal antibody that CAT itself has taken to this stage...

CAT-213
* CAT-213 is a human IgG4 monoclonal antibody that neutralizes eotaxin1
-- a chemokine protein that acts to attract eosinophils (a type of
white blood cell) into tissues, where they can degranulate causing
tissue damage. Eosinophils are thus believed to play a key role in
causing the inflammation and tissue damage that occurs in a variety of
allergic disorders, including asthma...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News